arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

bioAffinity Technologies, Inc.

BIAF
$7.93 ▼ -0.70 (-8.06%) at close
Industrials ·Services-Commercial Physical & Biological Research ·USServices-Commercial Physical & Biological Research
23 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

bioAffinity Technologies, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $41.4M
Dividend Yield
Revenue Growth 19.0%
Op. Margin -220.8%
ROIC -69.9%
FCF / Share $-0.63
Trailing P/E
Price / Book 14.3x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

23-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.51M
↑ +19.0%
Net Income Profit after all expenses
$-3.37M
↑ +17.1%
Operating Margin Operating profit as % of sales
-220.8%
↑ +17.5% 1th
FCF / Share Free cash flow per share
$-0.63
↑ +12.5%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
1
Returns
2
Financial Health
50
Cash Quality
45

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 6 years · 23 quarters